Achondroplasia Combo Therapy Shows Unprecedented Non-Linear Growth Benefits in Ascendis Pharma Trial
ASND sits 83% above its 52-week low of $124.06.
Summary
Ascendis Pharma reported new positive Week 52 data from its Phase 2 COACH trial for the combination therapy of TransCon CNP and TransCon hGH in children with achondroplasia. The data revealed accelerated benefits beyond linear growth, including unprecedented improvements in arm span, enhanced spinal canal dimensions, and improved lower limb alignment. Specifically, the combination therapy demonstrated superior improvements in interpedicular distance (IPD) compared to TransCon CNP monotherapy, indicating a potential to reduce nerve compression. This new information significantly broadens the potential efficacy profile of the treatment, suggesting substantial clinical utility beyond just height gain, which is highly material for patients and the company's valuation. This positive development follows the recent FDA Orphan Drug Exclusivity for TransCon CNP (YUVIWEL) as a monotherapy. Investors will closely monitor further long-term data and the progression of this combination therapy into later-stage clinical trials.
At the time of this announcement, ASND was trading at $226.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $124.06 to $248.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.